Fingolimod. Mitsubishi Pharma/Novartis.

Article Details

Citation
Copy to clipboard

Dumont FJ

Fingolimod. Mitsubishi Pharma/Novartis.

IDrugs. 2005 Mar;8(3):236-53.

PubMed ID
15772896 [ View in PubMed
]
Abstract

Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.

DrugBank Data that Cites this Article

Drugs